Analyst Mark Massaro from BTIG reiterated a Buy rating on Tempus AI, Inc. Class A and increased the price target to $85.00 from $75.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mark Massaro has given his Buy rating due to a combination of factors that highlight Tempus AI, Inc.’s strong performance and growth potential. The company has demonstrated robust revenue growth, particularly in its data and genomics segments, with a significant year-over-year increase. This growth is further supported by a substantial $200 million data deal with AstraZeneca, which underscores the value of Tempus’s data assets.
Additionally, Tempus has raised its revenue guidance for 2025, reflecting confidence in its future prospects. The company’s efforts to achieve positive adjusted EBITDA by the end of the year also contribute to the positive outlook. Furthermore, Tempus’s expansion into new areas such as cardiology and radiology, along with recent FDA approvals, indicate a promising pipeline that could drive future growth. These factors collectively justify the Buy rating and the increased price target of $85.
Massaro covers the Healthcare sector, focusing on stocks such as Personalis, Adaptive Biotechnologies, and CareDx. According to TipRanks, Massaro has an average return of -9.2% and a 31.13% success rate on recommended stocks.
In another report released on August 13, TD Cowen also maintained a Buy rating on the stock with a $72.00 price target.